The independent data monitoring committee (IDMC) recommended the continuation of VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma (PDAC), with no safety concerns raised VIRAGE remains on track to complete enrollment in the first half of 2024 As of December 31, 2023, Theriva Biologics reports $23.2 million in cash, which is expected to provide... Read More